Icosavax keeps up the excitement for its VLP ‘soccer balls,’ earning the RA Capital stamp of approval in $100M Series B

Roughly a year and a half since its last raise, Icosavax scored a fresh goal Wednesday morning in nabbing new funds for its soccer ball-like VLP vaccine tech. And the Seattle-based company is bringing in a high-profile set of new investors.

Icosavax unveiled a $100 million Series B, backed by...

Click to view original post